WASHINGTON—Donald Patrick McDonnell, Ph.D., has been awarded the Endocrine Society’s John D. Baxter Prize for Entrepreneurship for discovering hormone therapies for treating breast and prostate cancer ...
CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or its ...
(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low ...
MedPage Today on MSN
No survival benefit in advanced breast cancer with frontline CDK4/6 inhibition
Median overall survival of 4 years with upfront CDK4/6 inhibition or in second line ...
Researchers found cardiovascular drugs were associated with 24.7 percent of all medication errors, followed by antibiotics at 19.1 percent, electrolytes at 11.3 percent, endocrine drugs at 8.8 percent ...
The most common drug class associated with registered nurse (RN) medication errors (ME) was cardiovascular drugs. These errors accounted for 24.7% of such preventable ...
Despite major advances in oncology, drug resistance remains one of the principal obstacles to achieving durable responses and cure in cancer patients. Both ...
AstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy – even if they had very low levels of the ...
June 2 (Reuters) - AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab Enhertu slows the progression of breast cancer by about five months in women whose disease worsened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results